Navigation Links
Pharmos Issues Business Update on Dextofisopam Trial and Financing
Date:4/2/2009

toimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. These are available for licensing / partnering. On February 18, 2009, Pharmos Corporation and its Israeli subsidiary, Pharmos Ltd., entered into an Asset Purchase Agreement with Reperio Pharmaceuticals Ltd. for the sale of the patent rights and technical know-how related to the compound known as PRS-639,058 and certain follow-on molecules.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
3. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
4. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
7. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
9. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
10. European Unions CHMP Issues Positive Opinion on Sugammadex
11. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... What can be expected from the ... grow at the fastest rates? Visiongain ,s brand ... data, trends, opportunities and prospects there. Our ... graphs. Discover the most lucrative areas in the industry ... you assess forecasted sales at overall world market and ...
Breaking Medicine Technology:Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... 2011 The University of California, Los Angeles (UCLA) ... soon become the third oncology research center in the ... a privately held medical device company. ViewRay,s new research ... patented combination of radiotherapy delivery and simultaneous magnetic resonance ...
... Nearly three quarters of the medical ... from developed markets, but the next wave of growth is ... unique needs of the India market, according to preliminary findings ... which were presented today at AdvaMed 2011, the annual MedTech ...
Cached Medicine Technology:UCLA Health System - Jonsson Comprehensive Cancer Center to Acquire ViewRay Radiation Therapy Research System 2Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 2Made in India, for India, is Next Wave of Growth for Region's Medical Technology Sector 3
(Date:7/30/2015)... ... July 30, 2015 , ... Google recently announced that it will be ... As discussed in a June 8, 2015 article published by Nasdaq , the ... been caused by its computer-driven cars, which such industry players as Tesla CEO Elon ...
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ” ... a look at small, medium, and large businesses making an impact in their ... business review and shared with viewers how DevExpress has provided software development tools ...
(Date:7/30/2015)... ... , ... 24/7 Care At Home, a high-quality provider of comprehensive home health ... Centers for Medicare and Medicaid (CMS) have awarded its agency the highest star rating ... Home’s agency is one of three top Orange County agencies to earn the 5-Star ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never greater than ... to patients as well as visiting friends and family during these critical moments, hospitals ... The stations - powered by ChargeItSpot , a Philadelphia-based startup that recently secured ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s extensive ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects ... editorial and marketing groups will help spread the news about the center’s leading-edge ...
Breaking Medicine News(10 mins):Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... Financial Flexibility - , , LAVAL, QC, June 25 ... ) today announced it has amended its debt facility agreement ... ). , Based on regulatory approval and recent launch of ... has been able to establish more favourable repayment terms. Under ...
... , Social commentator and vegan Ben Shaberman collects humorous ... , BALTIMORE, June 25 Apprentice House announces publication ... which guides readers through the world of being vegan, ... world of carnivores. Whether explaining how vegetarian guys ...
... , Product innovation designed to meet growing consumer demand for ... new line of High Fiber soups from Progresso(R), available in ... for taste, nutritional value and variety among ready-to-serve soups. , ... ingredient to positively impact health, 9 in 10 Americans are ...
... Can Help Americans Improve their Diets, Health and Energy , , NEW YORK, ... Friedrich today announced they are teaming up to help Americans make fitness and healthy ... and exercise, the partners will debut their " EB to ... etter + E at ...
... ... published in the British Journal of Nutrition (a Cambridge University Journal), clearly shows that ... , ... 2009 -- In a revolutionary healthcare finding, a peer-reviewed clinical study published in the ...
... , ... effort to more accurately reflect the service their Recruiters provide and the relationships they ... of their Recruiters to Career Consultants. , ... Omaha, NE (PRWEB) June 25, 2009 -- In an effort ...
Cached Medicine News:Health News:Labopharm amends debt facility agreement with Hercules 2Health News:Labopharm amends debt facility agreement with Hercules 3Health News:The Vegan Monologues Asks the Burning Question: Is That a Carrot in Your Pocket? 2Health News:Progresso(R) to Launch New High Fiber Soup Line in Fall 2009 2Health News:Eggland's Best and Award-Winning Fitness Trainer Cathe Friedrich Launch National Health and Fitness Program 2Health News:Eggland's Best and Award-Winning Fitness Trainer Cathe Friedrich Launch National Health and Fitness Program 3Health News:Eggland's Best and Award-Winning Fitness Trainer Cathe Friedrich Launch National Health and Fitness Program 4Health News:New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33% 2Health News:Traveling Healthcare Staffing Company, Medical Solutions, Announces a Ttitle change for its Recruiters to Career Consultants 2Health News:Traveling Healthcare Staffing Company, Medical Solutions, Announces a Ttitle change for its Recruiters to Career Consultants 3
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... high throughput primary or backup instrument, ... performance and reliability equal to or ... The advanced technology of the AUTION ... delivers reproducible and accurate results, limiting ...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity ...
... Estrone Sulfate (E1S) is the most abundant ... as normal men [1,2]. Estrone Sulfate is ... and has a longer half-life in blood ... generally parallel those of estrone and estradiol, ...
Medicine Products: